Moderna's Cancer Vaccine Data Land With a Thud of Conflicting Verdicts
Published on 10/29/2026 at 17:01 | Editorial boerse-global.de
Moderna shares climbed 4.4% as the formal release and presentation of its melanoma trial data gave the stock a fresh tailwind, with media reports tying the advance directly to the clinical readout. Yet the same day brought two opposite verdicts from the analyst community, underlining how much disagreement now surrounds the company's valuation.
A 42% Risk Cut, and a CEO on the Record
The combination of Moderna's personalized cancer vaccine Intismeran with Merck's Keytruda met the primary goals of a Phase 3 trial enrolling more than 1,100 melanoma patients. According to company figures, the combined risk of relapse or death fell 42% versus Keytruda alone, while the risk of distant metastasis or death dropped 38%. The results were presented at the ESMO congress, with each comparison benchmarked against Keytruda monotherapy.
CEO Stéphane Bancel defended the findings in an interview with the Wall Street Journal, arguing that for the first time an add-on to Keytruda has outperformed Keytruda by itself. He expects the incremental benefit to become more pronounced with longer follow-up — a projection that matters to investors but does not yet amount to proven long-term treatment success. The data discussed so far, per Bancel, reflect the trajectory two years after vaccination.
Two Houses, Two Directions
Piper Sandler on Monday lifted its price target on Moderna to $230 from $167 while keeping its "Overweight" rating, according to media reports — a change in the target mark, not in the underlying recommendation. William Blair moved the other way on Tuesday, cutting its rating to "Market Perform" from "Outperform," citing valuation after the sharp run-up in the share price.
Should investors sell immediately? Or is it worth buying Moderna?
The split captures the central tension: clinical progress on one side, economic uncertainty on the other. Positive trial endpoints alone answer neither the question of the eventual patient population nor that of the therapy's commercial value. A benefit on the combined endpoint of relapse or death should not be equated with a secured long-term survival advantage — overall survival remains under investigation, and that distinction stays pivotal for how the treatment is valued.
What the Bull Case Still Needs to Prove
The decisive test is not the already-reported risk reduction but whether the gap to Keytruda alone holds or widens over time. Bancel's comparison to Keytruda's early success offers a strategic perspective rather than confirmation of a similar commercial trajectory; investors must separate management's confidence from results that longer follow-up has yet to deliver. Nor is the transferability to other cancer types settled. The melanoma data can serve as a foundation for further development steps, but they do not automatically establish comparable benefit outside this disease.
Intismeran is being studied in ten clinical trials, and Bancel sees potential applications beyond melanoma, naming early-stage lung cancer among them. That opens a development horizon, not a confirmed additional market. The manufacturers are already in talks with regulators, though approval remains a pending decision — the treatment has not yet been cleared by the US Food and Drug Administration. Any expansion would require its own robust clinical evidence.
A Sample Problem and a Legal Sidelight
One concrete limiting factor concerns the raw material for the personalized therapy: Bancel said that in 17% of the people initially examined, the tumor sample was insufficient for an individual vaccine. That is relevant to potential use, even if it does not translate into a universal rate for later routine care. A negative scenario would not require a full clinical failure — it would gain weight if the incremental benefit persists but the practically reachable patient pool or the transferability falls short of expectations.
Moderna at a turning point? This analysis reveals what investors need to know now.
Separately, a law firm announced on October 23 an investigation of potential claims on behalf of Moderna buyers. Media reports noted that no established misconduct was alleged; the announcement concerned the review of possible claims, not the outcome of a completed proceeding.
November 6 as the Next Hard Data Point
The financial picture could reinforce the optimistic case. Moderna had held out up to 10% revenue growth for 2026 and reaffirmed that possibility in the second quarter. Such an operating trajectory would complement the clinical outlook without replacing it. On November 6, 2026, the company intends to publish third-quarter 2026 results alongside a business overview — making revenue guidance, cost control and liquidity checkable next to the clinical story. Whether its financial room to maneuver convincingly supports the development path will be the question that date begins to answer.
Ad
Moderna Stock: New Analysis - 29 October
Fresh Moderna information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
